Pathologic response and safety to neoadjuvant PD-1 inhibitors and chemotherapy in resectable squamous non-small-cell Lung cancer.

Liang Shi,Qiyi Meng,Li Tong,Hongxia Li,Yujie Dong,Chongyu Su,Zhe Liu

Frontiers in oncology（2022）

引用 2|浏览13

暂无评分

摘要

Neoadjuvant PD-1 inhibitors and chemotherapy are feasible therapies for resectable squamous NSCLC. It was associated with a 66.7% MPR rate, 39.7% pCR rate, and tolerable toxicity.

查看译文

关键词

neoadjuvant chemoimmunotherapy,pathologic response,programmed death-1 inhibitors,resectable non-small-cell lung cancer,squamous cell carcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要